NVO News and Press, Novo Nordisk A/S From 03/06/26

2026-03-06 18:25:00 ET Is Novo Nordisk (NYSE: NVO) a bargain or a value trap as it battles Eli Lilly (NYSE: LLY) for GLP‑1 leadership, execution credibility, and premium growth? Watch the video below to see how investors might navigate this high‑stakes rivalry....

2026-03-06 18:13:23 ET Intro When Novo Nordisk A/S ( NVO ) CEO Maziar "Mike" Doustdar and Eli Lilly and Company ( LLY ) CEO David Ricks stood shoulder to shoulder in the White House Oval Office during their drug pricing deal ‑announcement ceremony with the...

2026-03-06 09:30:00 ET Eli Lilly: Are The Best Days Over? It seems like the market is ready to look past the previous winners in the healthcare sector, and that includes Eli Lilly ( LLY ), unfortunately. It shouldn't have escaped the lens of investors that LLY gained just under ...

2026-03-06 08:17:19 ET More on Novo Nordisk A/S Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks Novo’...

2026-03-06 06:05:00 ET Listen below or on the go via Apple Podcasts and Spotify U.S. issues 30 day waiver (1:00) and considers requiring permits for global AI chip sales (2:45) China approves Pfizer’s GLP-1 (4:00)... Read the full article on Seeking Alph...

2026-03-06 02:27:55 ET More on Pfizer Pfizer: Obesity Hype And Vaccine Policy Shocks Pfizer's Portfolio Renewal In Progress - High Yields For The Patient Pfizer's Quiet Cash Comeback Pfizer-backed Priovant wins FDA priority review for lead asset FDA r...

2026-03-05 16:25:00 ET A surprising obesity trial result has shaken confidence in Novo Nordisk (NYSE: NVO) and sharpened the spotlight on Eli Lilly (NYSE: LLY) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors. *Thi...

2026-03-05 14:03:42 ET A month after the Bureau of Labor Statistics favorably low January Consumer Price Index figures , it will release February’s report on Wednesday, March 11. The upcoming report matters more than ever for two main reasons. First, energy inflation risks ar...

2026-03-05 06:00:58 ET Performance assessment Pfizer ( PFE ) has outperformed the S&P500 broader market index since my last update on the stock: Performance since Author's Last Article on PFE (Seeking Alpha, Author's Last Article on PFE) Read the fu...

2026-03-04 08:58:43 ET More related stories CoreWeave Looks Broken... The Backlog Says Otherwise CoreWeave Is Attractively Valued, But Execution Is Crucial CoreWeave: Unapologetic Capex Meets Unforgiving Economics Dycom Industries jumps after record Q4 result...